Vir Biotechnology Announces First Patient Dosed in Groundbreaking Phase 2 Trial of VIR-2482 for Antibody Prophylaxis of Influenza A
18 oct. 2022 08h00 HE
|
Vir Biotechnology, Inc.
– First clinical trial evaluating the role of a monoclonal antibody in preventing seasonal flu – – Announcement follows recent U.S. government award from the Biomedical Advanced Research and...
![VaxInnate Logo](/news-release/logo/313305/0/313305.jpg?lastModified=12%2F09%2F2016%2023%3A16%3A03&size=2)
VaxInnate Appoints Former CDC Division Chief Thomas Monath to Board of Directors
17 juin 2015 08h00 HE
|
VaxInnate Corporation
Cranbury, NJ, June 17, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a breakthrough vaccine technology platform, today announced the appointment of Thomas P. Monath,...
![VaxInnate Logo](/news-release/logo/313305/0/313305.jpg?lastModified=12%2F09%2F2016%2023%3A16%3A03&size=2)
VaxInnate to Present at Needham & Company 14th Annual Healthcare Conference
07 avr. 2015 08h00 HE
|
VaxInnate Corporation
Cranbury, NJ, April 7, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a
breakthrough vaccine technology, today announced plans to present
at the Needham & Company 14th...
![VaxInnate Logo](/news-release/logo/313305/0/313305.jpg?lastModified=12%2F09%2F2016%2023%3A16%3A03&size=2)
VaxInnate Initiates Phase 1b/2 Clinical Trial of Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, in Elderly
08 déc. 2014 08h00 HE
|
VaxInnate Corporation
Cranbury, NJ, Dec. 8, 2014 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a
breakthrough vaccine technology platform, today announced the
initiation of a double-blind,...